CNIH2 Inhibitors
CNIH2 inhibitors constitute a specialized category of compounds meticulously crafted to modulate the activity of CNIH2 through indirect mechanisms, with a primary emphasis on the Src kinase pathway. Src kinase, a pivotal mediator in cellular signaling, plays a central role in phosphorylating and regulating CNIH2, thereby exerting influence over various cellular processes associated with proper Src kinase signaling. The selected inhibitors, including PP2, AZD0530, Dasatinib, Saracatinib, Bosutinib, PP1, KX2-391, WH-4-023, AZM475271, AP24534, SU6656, and Dasatinib Monohydrate, collectively share a commonality in their capacity to disrupt Src kinase activation. The significance of Src kinase in orchestrating the phosphorylation and regulation of CNIH2 underscores the intricate nature of their interdependence.
These inhibitors, by perturbing Src kinase activation, induce alterations in the phosphorylation patterns and subsequent functional dynamics of CNIH2. This interference reverberates through cellular processes intricately linked to the balanced orchestration of Src kinase signaling, culminating in a nuanced impact on CNIH2 activity. The intricacies of the interplay between Src kinase and CNIH2 within cellular signaling networks highlight the complexity of their relationship, tightly regulated to maintain cellular homeostasis. Functioning as invaluable tools, these inhibitors offer a means to dissect the intricate regulatory mechanisms governing CNIH2, thereby providing a deeper understanding of its role in cellular processes. This chemical class serves as a foundation for unraveling the detailed interactions between CNIH2 and Src kinase, shedding light on strategies. The continued exploration of this class of chemicals holds promise for advancing our comprehension of the intricate signaling cascades involving CNIH2 and Src kinase. It opens avenues for targeted interventions in conditions where dysregulation of CNIH2 is implicated, expanding our knowledge base for future investigations into the molecular intricacies of cellular signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a selective Src family kinase inhibitor, PP2 disrupts the activation of Src, which phosphorylates and modulates CNIH2 function. This indirect inhibition impacts cellular processes dependent on proper Src kinase signaling, subsequently affecting CNIH2. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
AZD0530 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a dual Src/Abl kinase inhibitor, AZD0530 disrupts the activation of Src, impacting the phosphorylation and function of CNIH2. This indirect inhibition modulates cellular processes dependent on Src kinase signaling, influencing CNIH2 activity. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $86.00 $145.00 | 6 | |
PP1 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a selective Src family kinase inhibitor, PP1 disrupts the activation of Src, which phosphorylates and modulates CNIH2 function. This indirect inhibition impacts cellular processes dependent on proper Src kinase signaling, subsequently affecting CNIH2. | ||||||
KX2-391 | 897016-82-9 | sc-364520 sc-364520A | 5 mg 50 mg | $180.00 $1140.00 | ||
KX2-391 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As an oral Src inhibitor, KX2-391 disrupts Src activation, leading to altered phosphorylation and function of CNIH2. This indirect inhibition modulates cellular processes dependent on Src kinase signaling, influencing CNIH2 activity. | ||||||
WH-4-023 | 837422-57-8 | sc-507457 | 10 mg | $172.00 | ||
WH-4-023 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a potent dual Src/Abl kinase inhibitor, WH-4-023 disrupts the activation of Src, impacting the phosphorylation and function of CNIH2. This indirect inhibition modulates cellular processes dependent on Src kinase signaling, influencing CNIH2 activity. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP24534 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a multi-kinase inhibitor, AP24534 disrupts Src activation, leading to altered phosphorylation and function of CNIH2. This indirect inhibition modulates cellular processes dependent on Src kinase signaling, influencing CNIH2 activity. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a selective Src family kinase inhibitor, SU6656 disrupts the activation of Src, which phosphorylates and modulates CNIH2 function. This indirect inhibition impacts cellular processes dependent on proper Src kinase signaling, subsequently affecting CNIH2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib Monohydrate inhibits CNIH2 indirectly by targeting the Src kinase pathway. As a multi-kinase inhibitor, Dasatinib Monohydrate disrupts Src activation, leading to altered phosphorylation and function of CNIH2. This indirect inhibition modulates cellular processes dependent on Src kinase signaling, influencing CNIH2 activity. | ||||||